Regeneron Surges 3.11% on Groundbreaking Myeloma Trial Data – Is This the Catalyst for a New Bull Run?

Summary
• Regeneron (REGN) surges 3.11% to $714.18, hitting an intraday high of $717.88
• Lynozyfic trial data shows 100% residual disease eradication in multiple myeloma patients
• RBC and Canaccord maintain mixed ratings, with price targets ranging from $708 to $1,057

Regeneron’s stock is surging on the back of transformative clinical data for its dual-target antibody Lynozyfic, which eliminated residual multiple myeloma in all 18 trial participants. With the stock trading near its 52-week high of $790.98 and a dynamic P/E of 15.38, investors are weighing the implications of this breakthrough against regulatory risks and sector dynamics.

Lynozyfic’s Trial Success Ignites Optimism
Regeneron’s 3.11% intraday surge is directly tied to preliminary data from its Lynozyfic trial, where the drug eradicated residual multiple myeloma in all 18 participants. This outcome, presented at the American Society of Hematology, positions Lynozyfic as a potential alternative to bone marrow transplants, a grueling standard-of-care. The trial’s success underscores Regeneron’s pipeline strength and validates its dual-antibody innovation, which targets both CD3 and BCMA proteins. Analysts highlight that this could expand Lynozyfic’s market beyond its current indication for recurrent myeloma, driving long-term revenue growth.

Biotech Sector Gains Momentum as Amgen Leads – Regeneron Outperforms on Pipeline Optimism
The biotech sector, led by Amgen (AMGN) with a 0.64% intraday gain, is seeing renewed interest amid positive clinical developments. Regeneron’s 3.11% move outpaces Amgen’s modest rise, reflecting investor confidence in its differentiated pipeline. While Amgen’s growth is driven by stable oncology and inflammation sales, Regeneron’s dual-antibody innovation and Lynozyfic’s trial success position it as a high-conviction play. The sector’s 14.23% CAGR forecast through 2033 further supports long-term optimism, though regulatory risks for Regeneron persist due to EYLEA competition and manufacturing challenges.

Options Playbook: Leverage Lynozyfic’s Momentum with High-Gamma Calls
• 200-day MA: $598.90 (below) • RSI: 41.89 (oversold) • MACD: 18.27 (bullish divergence) • Bollinger Bands: $657.88–$795.76 (strong support/resistance)

Regeneron’s technicals suggest a short-term bullish setup, with the stock trading near its 52-week high and RSI indicating oversold conditions. The 30-day MA at $700.77 and 200-day MA at $598.90 highlight a strong upward trend. For options, focus on high-gamma, high-leverage calls to capitalize on volatility. Two top picks from the options chain are:

• REGN20251219C720 (Call, $720 strike, 12/19 expiry):
- IV: 26.85% (moderate)
- Leverage: 64.49%
- Delta: 0.466 (moderate sensitivity)
- Theta: -1.809 (high time decay)
- Gamma: 0.0125 (high sensitivity to price swings)
- Turnover: 4,005 (liquid)
- Payoff at 5% upside ($749.89): $29.89/share
- Ideal for aggressive bulls expecting a breakout above $717.88.

• REGN20251219C730 (Call, $730 strike, 12/19 expiry):
- IV: 25.32% (moderate)
- Leverage: 109.30%
- Delta: 0.3369 (lower sensitivity)
- Theta: -1.4038 (high time decay)
- Gamma: 0.01217 (high sensitivity)
- Turnover: 1,730 (liquid)
- Payoff at 5% upside ($749.89): $19.89/share
- Suited for high-risk, high-reward plays if the stock breaks above $717.88.

Aggressive bulls may consider REGN20251219C720 into a bounce above $717.88, while REGN20251219C730 offers leveraged exposure for a sustained move toward $790.98.

Backtest Regeneron Stock Performance
The backtest of Regeneron (REGN) after a 3% intraday increase from 2022 to the present shows favorable performance metrics. The 3-day win rate is 51.72%, the 10-day win rate is 54.77%, and the 30-day win rate is 57.40%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest was 1.88%, which occurred on day 54, suggesting that REGN can deliver modest gains following a 3% intraday surge.

Position for a Breakout – Lynozyfic’s Momentum Could Define 2026
Regeneron’s 3.11% surge is driven by transformative clinical data for Lynozyfic, which could redefine multiple myeloma treatment. While the stock faces regulatory and competitive risks, its technicals and options liquidity suggest a strong near-term bias. Watch for a breakout above $717.88 (intraday high) to confirm bullish momentum, with a stop-loss below $692.50 (intraday low). The sector leader, Amgen (AMGN), is up 0.64%, but Regeneron’s pipeline-driven optimism positions it as a high-conviction play. Position for a breakout with REGN20251219C720 and monitor the 52-week high of $790.98 as a key target.